Celgene Corporation (CELG) : Boston Family Office reduced its stake in Celgene Corporation by 1.29% during the most recent quarter end. The investment management company now holds a total of 149,129 shares of Celgene Corporation which is valued at $15,421,430 after selling 1,942 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Apr 26, 2016.Celgene Corporation makes up approximately 2.03% of Boston Family Office’s portfolio.
Celgene Corporation opened for trading at $103.25 and hit $105.02 on the upside on Monday, eventually ending the session at $104.97, with a gain of 1.51% or 1.56 points. The heightened volatility saw the trading volume jump to 49,18,748 shares. Company has a market cap of $82,051 M.
Other Hedge Funds, Including , Regent Investment Management reduced its stake in CELG by selling 245 shares or 0.59% in the most recent quarter. The Hedge Fund company now holds 41,559 shares of CELG which is valued at $4,593,101. Celgene Corporation makes up approx 2.51% of Regent Investment Management’s portfolio. Piershale Financial Group added CELG to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $10,734. Celgene Corporation makes up approx 0.01% of Piershale Financial Group’s portfolio.Patten Patten Inctn boosted its stake in CELG in the latest quarter, The investment management firm added 6,150 additional shares and now holds a total of 57,720 shares of Celgene Corporation which is valued at $6,195,665. Celgene Corporation makes up approx 0.88% of Patten Patten Inctn’s portfolio.
On the company’s financial health, Celgene Corporation reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.27. The company had revenue of $2511.60 million for the quarter, compared to analysts expectations of $2577.08 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 135 from a previous price target of $150 .
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.